Improve Medical Instruments Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Improve Medical Instruments.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Life Sciences earnings growth | 31.8% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | None |
| Last updated | n/a |
Recent future growth updates
No updates
Recent updates
Improve Medical Instruments Co., Ltd.'s (SZSE:300030) Price Is Right But Growth Is Lacking After Shares Rocket 28%
Oct 28
Improve Medical Instruments Co., Ltd. (SZSE:300030) Held Back By Insufficient Growth Even After Shares Climb 46%
Sep 10Revenues Working Against Improve Medical Instruments Co., Ltd.'s (SZSE:300030) Share Price Following 26% Dive
Jun 06A Look At The Fair Value Of Improve Medical Instruments Co., Ltd. (SZSE:300030)
Jun 04Benign Growth For Improve Medical Instruments Co., Ltd. (SZSE:300030) Underpins Stock's 27% Plummet
Apr 16Improve Medical Instruments Co., Ltd.'s (SZSE:300030) 25% Dip In Price Shows Sentiment Is Matching Revenues
Feb 26In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Improve Medical Instruments has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 9/30/2024 | 594 | -109 | 17 | 88 | N/A |
| 6/30/2024 | 618 | -79 | 49 | 118 | N/A |
| 3/31/2024 | 627 | -80 | 59 | 114 | N/A |
| 12/31/2023 | 645 | -63 | 36 | 80 | N/A |
| 9/30/2023 | 654 | -137 | 27 | 56 | N/A |
| 6/30/2023 | 678 | -152 | -17 | 7 | N/A |
| 3/31/2023 | 690 | -147 | 8 | 44 | N/A |
| 1/1/2023 | 711 | -198 | -16 | 42 | N/A |
| 9/30/2022 | 740 | -73 | -19 | 51 | N/A |
| 6/30/2022 | 736 | -107 | -13 | 65 | N/A |
| 3/31/2022 | 749 | -52 | 36 | 115 | N/A |
| 1/1/2022 | 800 | 19 | 101 | 172 | N/A |
| 9/30/2021 | 886 | -11 | 159 | 230 | N/A |
| 6/30/2021 | 934 | 147 | 144 | 208 | N/A |
| 3/31/2021 | 1,002 | 185 | 112 | 175 | N/A |
| 12/31/2020 | 919 | 163 | 84 | 141 | N/A |
| 9/30/2020 | 787 | 211 | 22 | 72 | N/A |
| 6/30/2020 | 718 | 115 | 50 | 104 | N/A |
| 3/31/2020 | 611 | 32 | -13 | 42 | N/A |
| 12/31/2019 | 575 | 26 | -5 | 49 | N/A |
| 9/30/2019 | 568 | -129 | -15 | 43 | N/A |
| 6/30/2019 | 550 | -133 | -15 | 43 | N/A |
| 3/31/2019 | 537 | -136 | 29 | 79 | N/A |
| 12/31/2018 | 550 | -137 | 6 | 56 | N/A |
| 9/30/2018 | 566 | 11 | 112 | 186 | N/A |
| 6/30/2018 | 574 | 11 | N/A | 181 | N/A |
| 3/31/2018 | 564 | 9 | N/A | 181 | N/A |
| 12/31/2017 | 550 | 11 | N/A | 142 | N/A |
| 9/30/2017 | 534 | 24 | N/A | 60 | N/A |
| 6/30/2017 | 528 | 29 | N/A | 49 | N/A |
| 3/31/2017 | 521 | 29 | N/A | -27 | N/A |
| 12/31/2016 | 517 | 30 | N/A | 23 | N/A |
| 9/30/2016 | 536 | 32 | N/A | 22 | N/A |
| 6/30/2016 | 538 | 37 | N/A | 26 | N/A |
| 3/31/2016 | 558 | 39 | N/A | 84 | N/A |
| 12/31/2015 | 545 | 40 | N/A | -8 | N/A |
| 9/30/2015 | 512 | 41 | N/A | -132 | N/A |
| 6/30/2015 | 498 | 52 | N/A | -168 | N/A |
| 3/31/2015 | 476 | 54 | N/A | -171 | N/A |
| 12/31/2014 | 462 | 53 | N/A | -108 | N/A |
| 9/30/2014 | 463 | 58 | N/A | 25 | N/A |
| 6/30/2014 | 440 | 53 | N/A | 72 | N/A |
| 3/31/2014 | 409 | 50 | N/A | 53 | N/A |
| 12/31/2013 | 397 | 46 | N/A | 44 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if 300030's forecast earnings growth is above the savings rate (2.8%).
Earnings vs Market: Insufficient data to determine if 300030's earnings are forecast to grow faster than the CN market
High Growth Earnings: Insufficient data to determine if 300030's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if 300030's revenue is forecast to grow faster than the CN market.
High Growth Revenue: Insufficient data to determine if 300030's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 300030's Return on Equity is forecast to be high in 3 years time